Capstan Therapeutics to Participate in 45th Annual Goldman Sachs Global Healthcare Conference
Capstan Therapeutics, Inc. ("Capstan"),a biotechnology company dedicated to advancing in vivo reprogramming of cells through RNA delivery using targeted lipid nanoparticles (tLNP), today announced that company management will participate in the upcoming 45th Annual Goldman Sachs Global Healthcare Conference, being held between June 10-13, 2024 at the Loews Miami Beach Hotel in Miami Beach, FL. Capstan will be hosting one-on-one meetings with investors.
Capstan is a biotechnology company with a mission to multiply the therapeutic possibilities for patients by developing targeted in vivo RNA technologies. Our core platform technology comprises proprietary tLNPs that are composed of LNPs conjugated with a recombinant protein binder, such as a monoclonal antibody. tLNPs are designed to deliver payloads, including mRNA or gene editing tools, capable of reprogramming specific cell types in vivo. This platform technology has the potential to generate transformative therapies with possible applications across a broad range of disease areas, including autoimmune disorders, oncology, fibrosis, and monogenic blood disorders. For more information, please visit www.capstantx.com and follow us on LinkedIn.
The report "Anti-Migrating Agent Market by Type (Non-ionic, Anionic, Cationic, Amphoteric), Grades (Technical, Food, Pharmaceutical), Application, Chemistry (Organic, Inorganic), End-Use Industry (Textile, Plastics, Paper), and Region - Global...
Gupshup, the world's leading Conversation Cloud, in collaboration with Meta, the Sudan Medical Specialization Board and non-profit Shabaka today announced the launch of a telemedicine chatbot providing healthcare access for Sudanese refugees in...
The revenue in June for Zinzino's sales markets increased by 13% and amounted to SEK 148.5 (131.4) million. Faun Pharma's external sales decreased and amounted to SEK 5.8 (8.5) million. Overall, the Group increased revenues by 10% to SEK 154.3...
The global Specialty Enzymes Market size is estimated to be valued at USD 6.1 billion in 2024 and is projected to reach USD 9.2 billion by 2029, recording a CAGR of 8.5% from 2024 to 2029 according to a report published by MarketsandMarketstm. The...
Kvantify, a leading quantum software start-up, has announced the successful closure of a EUR 10 million seed round. This funding will enable Kvantify to strengthen its position as a global leader in quantum computing, with an initial focus on...
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Cytotoxic Drugs and HPAPI Manufacturing Market- (Type of Product (HPAPI and highly potent finished dosage form), Company Size (Small, Mid-sized, Large,...
